膀胱癌辅助放疗:根治性膀胱切除术后辅助放疗或观察的III期多中心随机对照试验
该III期随机试验纳入根治性膀胱切除术后高危非转移性尿路上皮肌层浸润性膀胱癌患者,比较辅助放疗与观察。
要点
- 高危MIBC根治术后辅助盆腔IMRT可显著改善2年局部区域控制。
- 辅助放疗未增加严重毒性,但DFS、BCSS和OS差异未达统计学显著。
- 入组患者多数接受新辅助化疗,无人接受免疫治疗。
核心结论
- 根治性膀胱切除术后辅助盆腔IMRT在围手术期化疗基础上可改善高危尿路上皮MIBC的局部区域控制,且未增加严重毒性。
研究设计与样本
- 多中心III期随机对照试验,纳入根治性膀胱切除术后高危非转移性尿路上皮MIBC患者153例,按1:1随机分配至辅助放疗组(77例)或观察组(76例)。
- 随机分层因素为淋巴结受累(是/否)和化疗时机(新辅助/辅助/无)。
- 放疗为保留造口的IG-IMRT,剂量50.4Gy分28次,照射膀胱切除床和盆腔淋巴结。
- 主要终点为2年局部区域无复发生存率(LRFS),次要终点为无病生存(DFS)、膀胱癌特异生存(BCSS)和总生存(OS)。
主要发现
- 2年DFS放疗组71.6%对观察组58.7%,HR 0.62(95%CI 0.36-1.05)。
- 2年BCSS放疗组79.6%对观察组65.0%,HR 0.59(95%CI 0.33-1.10)。
- 2年OS放疗组70.4%对观察组57.4%,HR 0.78(95%CI 0.49-1.26)。
- 患者中pT3-T4占62%,pN+占41%,超过90%接受全身化疗(71%新辅助,20%辅助),无人接受免疫治疗。
关键数值与推荐
- 高危定义为根治性膀胱切除术后具有以下任一因素:T3-4、N1-3、切缘阳性、清扫淋巴结≤10枚。
- 放疗剂量为50.4Gy分28次,采用保留造口的IG-IMRT照射膀胱切除床和盆腔淋巴结。
临床怎么用
- 对于根治性膀胱切除术后高危尿路上皮MIBC患者,可考虑在围手术期化疗基础上加用辅助盆腔IMRT以改善局部区域控制。
- 辅助放疗未增加严重毒性,但DFS、BCSS和OS的获益尚未达统计学显著,需结合个体情况权衡。
局限性
- 样本量较小(共153例),DFS、BCSS和OS的置信区间较宽且未达统计学显著。
- 无人接受免疫治疗,结果外推至当前免疫治疗时代需谨慎。
- 随访时间中位47个月,长期生存获益尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the primary analysis of a multicenter, phase III randomized trial of adjuvant radiotherapy (RT) after chemotherapy and radical cystectomy (RC) in patients with high-risk muscle-invasive bladder cancer (MIBC). METHODS: Patients with nonmetastatic urothelial MIBC at high risk after RC (any one of: T3-4, N1-3, margin positive, ≤10 nodes dissected) were randomly assigned 1:1 to adjuvant RT or observation (Obs), stratified by nodal involvement (yes/no) and chemotherapy (neoadjuvant/adjuvant/none). Stoma-sparing IG-IMRT 50.4Gy in 28 fractions was prescribed to the cystectomy bed and pelvic nodes. The primary end point was 2-year locoregional recurrence-free survival (LRFS), and the secondary end points were disease-free survival (DFS), bladder cancer-specific survival (BCSS), and overall survival (OS). RESULTS: From June 2016 to May 2024, 153 patients were randomly assigned (Obs = 76, RT = 77), with 62% and 41% of patients having pT3-T4 and pN+ stages, respectively. Over 90% of the patients received systemic chemotherapy (71% neoadjuvant and 20% adjuvant), and none received immunotherapy. After a median follow-up of 47 months, the 2-year LRFS was significantly higher with adjuvant RT versus observation (87.1% v 76.0%, hazard ratio [HR], 0.43 [95% CI, 0.20 to 0.96], P = .04). The DFS was 71.6% versus 58.7% (HR, 0.62 [95% CI, 0.36 to 1.05]), BCSS was 79.6% versus 65.0% (HR, 0.59 [95% CI, 0.33 to 1.10]), and OS was 70.4% versus 57.4% (HR, 0.78 [95% CI, 0.49 to 1.26]) for RT and Obs, respectively. CONCLUSION: Adjuvant pelvic IMRT after radical cystectomy and perioperative chemotherapy suggests an improvement in locoregional control in patients with high risk urothelial MIBC with no additional severe toxicity.
引用
- Murthy V, Maitre P, Pal M, et al. Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer. J Clin Oncol. 2026. PMID: 42166701. doi:10.1200/JCO-25-02093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。